Parallel Advisors’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $144K | Sell |
4,256
-1,157
| -21% | -$38.5K | ﹤0.01% | 1476 |
|
|
2026
Q1 | $163K | Buy |
5,413
+2,774
| +105% | +$89.2K | ﹤0.01% | 1287 |
|
|
2025
Q4 | $82.4K | Sell |
2,639
-663
| -20% | -$16.3K | ﹤0.01% | 1576 |
|
|
2025
Q3 | $66.7K | Buy |
3,302
+300
| +10% | +$5.27K | ﹤0.01% | 1647 |
|
|
2025
Q2 | $50.3K | Buy |
3,002
+480
| +19% | +$7.75K | ﹤0.01% | 1721 |
|
|
2025
Q1 | $38.8K | Sell |
2,522
-173
| -6% | -$3.09K | ﹤0.01% | 1781 |
|
|
2024
Q4 | $59.4K | Buy |
2,695
+215
| +9% | +$3.91K | ﹤0.01% | 1540 |
|
|
2024
Q3 | $44.7K | Hold |
2,480
| – | – | ﹤0.01% | 1689 |
|
|
2024
Q2 | $40.3K | Buy |
2,480
+1,927
| +348% | +$29.7K | ﹤0.01% | 1632 |
|
|
2024
Q1 | $7.8K | Buy |
553
+6
| +1% | +$76 | ﹤0.01% | 2400 |
|
|
2023
Q4 | $5.71K | Buy |
+547
| New | +$5.11K | ﹤0.01% | 2483 |
|
|
2023
Q2 | – | Sell |
-78
| Closed | -$690 | – | 3517 |
|
|
2023
Q1 | $690 | Hold |
78
| – | – | ﹤0.01% | 3036 |
|
|
2022
Q4 | $711 | Buy |
78
+42
| +117% | +$366 | ﹤0.01% | 2970 |
|
|
2022
Q3 | $0 | Sell |
36
-174
| -83% | -$1.54K | ﹤0.01% | 3490 |
|
|
2022
Q2 | $2K | Sell |
210
-56
| -21% | -$488 | ﹤0.01% | 2644 |
|
|
2022
Q1 | $2K | Sell |
266
-1,160
| -81% | -$9.68K | ﹤0.01% | 2633 |
|
|
2021
Q4 | $11K | Buy |
1,426
+1,405
| +6,690% | +$12.7K | ﹤0.01% | 2084 |
|
|
2021
Q3 | $0 | Sell |
21
-232
| -92% | -$2.17K | ﹤0.01% | 3264 |
|
|
2021
Q2 | $3K | Hold |
253
| – | – | ﹤0.01% | 2496 |
|
|
2021
Q1 | $3K | Hold |
253
| – | – | ﹤0.01% | 2407 |
|
|
2020
Q4 | $2K | Buy |
253
+161
| +175% | +$1.54K | ﹤0.01% | 2354 |
|
|
2020
Q3 | $1K | Sell |
92
-147
| -62% | -$1.55K | ﹤0.01% | 2495 |
|
|
2020
Q2 | $2K | Buy |
+239
| New | +$2.7K | ﹤0.01% | 2237 |
|
|
2019
Q2 | – | Sell |
-186
| Closed | -$3K | – | 2432 |
|
|
2019
Q1 | $3K | Sell |
186
-27
| -13% | -$476 | ﹤0.01% | 2014 |
|
|
2018
Q4 | $3K | Hold |
213
| – | – | ﹤0.01% | 1792 |
|
|
2018
Q3 | $5K | Hold |
213
| – | – | ﹤0.01% | 1752 |
|
|
2018
Q2 | $5K | Sell |
213
-40
| -16% | -$816 | ﹤0.01% | 1619 |
|
|
2018
Q1 | $4K | Sell |
253
-157
| -38% | -$3.06K | ﹤0.01% | 1653 |
|
|
2017
Q4 | $8K | Buy |
410
+213
| +108% | +$3.2K | ﹤0.01% | 1396 |
|
|
2017
Q3 | $2K | Sell |
197
-945
| -83% | -$21.3K | ﹤0.01% | 1895 |
|
|
2017
Q2 | $37K | Buy |
1,142
+462
| +68% | +$14.3K | 0.01% | 781 |
|
|
2017
Q1 | $21K | Sell |
680
-320
| -32% | -$10.9K | ﹤0.01% | 952 |
|
|
2016
Q4 | $36K | Buy |
+1,000
| New | +$39.9K | 0.01% | 676 |
|
Other funds holding TEVA
HIIFS
PF
CI
MMH
MIFH
LIM
Parallel Advisors's TEVA Position: Q2 2026 in Review
Parallel Advisors reduced its Teva Pharmaceuticals (TEVA) stake by 21% in Q2 2026, selling an estimated $38.5K and leaving 4,256 shares worth $144K. The position accounts for ﹤0.01% of the portfolio, ranked #1476.
Parallel Advisors first reported a position in TEVA in Q4 2016 and has held it in 33 quarters since. The position peaked at $163K in Q1 2026. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.
- Parallel Advisors held 4,256 shares of Teva Pharmaceuticals worth $144K as of Q2 2026.
- Parallel Advisors sold 1,157 Teva Pharmaceuticals shares in Q2 2026, an estimated $38.5K.
- Teva Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #1476 holding.
- Parallel Advisors first reported a position in Teva Pharmaceuticals in Q4 2016 and has held it in 33 quarters since.
- Parallel Advisors's Teva Pharmaceuticals position peaked at $163K in Q1 2026.
- 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.
Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.